$1.29 Million in Sales Expected for Flexion Therapeutics Inc (FLXN) This Quarter

Equities analysts expect Flexion Therapeutics Inc (NASDAQ:FLXN) to post sales of $1.29 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Flexion Therapeutics’ earnings, with estimates ranging from $900,000.00 to $1.68 million. The company is scheduled to report its next earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Flexion Therapeutics will report full year sales of $1.29 million for the current year, with estimates ranging from $900,000.00 to $1.68 million. For the next year, analysts expect that the business will post sales of $25.45 million per share, with estimates ranging from $17.50 million to $41.70 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Flexion Therapeutics.

A number of research analysts recently commented on FLXN shares. BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a report on Friday, August 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price target (up previously from $34.00) on shares of Flexion Therapeutics in a report on Thursday, August 10th. Wells Fargo & Company set a $39.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Friday, October 6th. Northland Securities reaffirmed a “buy” rating and issued a $40.00 price target on shares of Flexion Therapeutics in a report on Wednesday, October 4th. Finally, Royal Bank Of Canada set a $44.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, September 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Flexion Therapeutics currently has an average rating of “Buy” and an average price target of $98.33.

In other news, insider Michael D. Clayman acquired 5,000 shares of Flexion Therapeutics stock in a transaction that occurred on Wednesday, November 8th. The shares were bought at an average cost of $23.60 per share, with a total value of $118,000.00. Following the transaction, the insider now directly owns 35,395 shares of the company’s stock, valued at approximately $835,322. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Neil Bodick acquired 2,700 shares of Flexion Therapeutics stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average cost of $24.49 per share, for a total transaction of $66,123.00. Following the completion of the transaction, the insider now directly owns 64,605 shares in the company, valued at $1,582,176.45. The disclosure for this purchase can be found here. Corporate insiders own 15.98% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Fiduciary Trust Co. purchased a new stake in Flexion Therapeutics in the 2nd quarter worth about $101,000. IFP Advisors Inc raised its position in Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 1,000 shares during the period. Advisor Group Inc. raised its position in Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 3,500 shares during the period. SG Americas Securities LLC purchased a new stake in Flexion Therapeutics in the 3rd quarter worth about $135,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in Flexion Therapeutics in the 3rd quarter worth about $235,000. 72.82% of the stock is currently owned by institutional investors.

Shares of Flexion Therapeutics (NASDAQ FLXN) traded down $0.26 during trading hours on Friday, hitting $25.44. 756,041 shares of the company were exchanged, compared to its average volume of 848,101. The company has a quick ratio of 12.93, a current ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics has a 1 year low of $16.51 and a 1 year high of $32.25.

TRADEMARK VIOLATION WARNING: “$1.29 Million in Sales Expected for Flexion Therapeutics Inc (FLXN) This Quarter” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://sportsperspectives.com/2017/12/05/1-29-million-in-sales-expected-for-flexion-therapeutics-inc-flxn-this-quarter.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply